三诺生物(300298) - 2022 Q1 - 季度财报

Revenue and Profit - Revenue for Q1 2022 reached ¥619,755,536.06, an increase of 23.27% compared to ¥502,767,712.79 in the same period last year[2] - Net profit attributable to shareholders was ¥65,293,271.66, up 45.22% from ¥44,960,957.80 year-on-year[2] - Net profit after deducting non-recurring gains and losses was ¥60,043,604.57, representing a 57.01% increase from ¥38,242,503.39 in the previous year[2] - Basic earnings per share increased by 47.16% to ¥0.1164 from ¥0.0791 in the same period last year[2] - The net profit for Q1 2022 was CNY 65,209,096.74, an increase of 46.4% compared to CNY 44,557,390.76 in Q1 2021[25] - Operating profit reached CNY 68,097,123.53, up from CNY 49,984,815.92, reflecting a growth of 36.2% year-over-year[25] - The total comprehensive income for the period was CNY 65,599,228.78, compared to CNY 56,191,602.15 in the previous year, reflecting a growth of 16.8%[25] Operating Costs and Expenses - Operating costs for Q1 2022 were ¥262,993,668.78, a 53.74% increase from ¥171,062,033.15 in the same period last year[6] - Management expenses increased by 32.80% to ¥46,423,072.18 from ¥34,956,637.22 year-on-year[6] - The total operating costs for Q1 2022 were CNY 556,118,354.19, up 28.0% from CNY 434,342,438.87 in the same period last year[24] - Research and development expenses for Q1 2022 were CNY 50,663,652.81, an increase from CNY 41,477,372.32 in Q1 2021, reflecting a growth of 22.5%[24] Cash Flow - Cash flow from operating activities showed a net outflow of ¥31,250,520.73, worsening by 17.83% compared to a net outflow of ¥26,521,957.92 in the previous year[2] - Cash flow from operating activities showed a net outflow of CNY 31,250,520.73, worsening from a net outflow of CNY 26,521,957.92 in the same period last year[27] - Investment activities resulted in a net cash outflow of CNY 42,335,286.66, compared to a significantly higher outflow of CNY 344,734,803.84 in Q1 2021[27] - Financing activities generated a net cash outflow of CNY 110,291,884.66, contrasting with a net inflow of CNY 153,925,341.73 in the previous year[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,114,260,871.65, a decrease of 0.95% from ¥4,153,513,571.28 at the end of the previous year[2] - The total assets of the company decreased slightly to CNY 4,114,260,871.65 from CNY 4,153,513,571.28, a decline of 0.9%[23] - The total liabilities decreased to CNY 1,302,692,016.01 from CNY 1,361,130,757.49, a reduction of 4.3%[22] - The company's accounts receivable rose to CNY 236,433,316.85 from CNY 209,664,837.62, indicating an increase of 12.8% year-over-year[21] - Inventory levels increased to CNY 365,478,035.13, up from CNY 330,796,256.02, representing a growth of 10.5%[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,812[9] - The largest shareholder, Li Shaobo, holds 25.26% of shares, totaling 142,685,648 shares[9] - The company repurchased 6,301,087 shares, accounting for 1.12% of the total share capital, with a total transaction amount of ¥158.51 million[10] - The company plans to repurchase shares with a total fund not exceeding RMB 200 million and not less than RMB 120 million, with a maximum repurchase price of RMB 35.00 per share[13] Investment Activities - The company reported a significant increase in investment income, reaching ¥1,503,248.28, compared to a loss of ¥14,290,775.19 in the same period last year, marking a 110.52% improvement[6] - The company has established a joint venture with EOFLOW, investing RMB 54 million for a 60% stake, with a total investment of RMB 90 million[16] - The joint venture, Changsha Funuo Medical Technology Co., Ltd., completed its business registration in January 2022[18] - The company issued 5 million convertible bonds with a total amount of RMB 50 million, which began trading on January 12, 2021, with a maturity of six years[15] - As of March 31, 2022, 306 convertible bonds have been converted into 859 shares of the company, leaving 4,999,694 convertible bonds outstanding[15] Governance and Management - The company revised its articles of association and various internal regulations to enhance management and governance structures[19] Cash and Cash Equivalents - The company's cash and cash equivalents at the end of the reporting period amounted to RMB 787,831,742.36, down from RMB 902,351,183.44 at the beginning of the year[20] - Cash and cash equivalents at the end of the period stood at CNY 405,422,683.95, down from CNY 663,363,588.54 at the end of Q1 2021[27]